<DOC>
	<DOCNO>NCT01523418</DOCNO>
	<brief_summary>The primary objective study evaluate safety Xarelto prophylaxis VTE Indian patient undergo elective TKR/THR</brief_summary>
	<brief_title>Study Observe Safety Xarelto VTE Prophlylaxis After Elective TKR ( Total Knee Replacement ) THR ( Total Hip Replacement )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patient either sex , undergo elective THR/TKR , , Rivaroxaban give thromboprophylaxis Patients willing give write informed consent Exclusion criterion must read conjunction local product information Patients UFH / LMWH therapy , fondaparinux vitamin K antagonists eligible . Patients history hypersensitivity active ingredient excipient : cellulose microcrystalline , croscarmellose sodium , lactose monohydrate , magnesium stearate , sodium lauryl sulfate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Xarelto</keyword>
	<keyword>Thromboembolism , Venous</keyword>
	<keyword>Orthopedic surgery</keyword>
	<keyword>Factor Xa inhibitor</keyword>
	<keyword>Observational study</keyword>
</DOC>